Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
55,700
-1,300 (-2.28%)
Apr 10, 2026, 3:30 PM KST
Market Cap729.15B +68.7%
Revenue (ttm)208.98B +29.5%
Net Income24.96B
EPS1,824.00
Shares Out13.09M
PE Ratio30.54
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume21,677
Average Volume49,957
Open57,700
Previous Close57,000
Day's Range55,700 - 58,000
52-Week Range23,500 - 72,700
Beta0.17
RSI46.76
Earnings DateApr 3, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Chemicals
Sector Materials
Founded 2000
Employees 426
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

Financial Statements